Madrigal's Cholesterol Drug Succeeds in Mid-Stage Trial Post author:Sam Post published:February 7, 2018 Post category:BioPharma MGL-3196 was well-tolerated with primarily mild and some moderate AEs. Source: BioSpace You Might Also Like Lupin Coughs Up $150 Million Cash for This New Jersey-Based Biopharma October 10, 2017 Cepheid Wins FDA Nod to Market Xpert Xpress Strep A October 4, 2017 Novartis Showcases 4 Potential Blockbusters in Its Late-Stage Pipeline November 13, 2017
